I
VKTX icon

InceptionR’s Viking Therapeutics VKTX Stock Holding History

InceptionR’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,708
Closed -$381K – 933
2026
Q1 		$381K Buy
+11,708
New +$376K 0.09% 404
2024
Q4 		– Sell
-3,429
Closed -$217K – 883
2024
Q3 		$217K Sell
3,429
-6,367
-65% -$374K 0.05% 553
2024
Q2 		$519K Buy
+9,796
New +$642K 0.15% 272

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

InceptionR's VKTX Position: Q2 2026 in Review

InceptionR sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 11,708 shares — an estimated $381K sold.

InceptionR first reported a position in VKTX in Q2 2024 and held it in 3 quarters. The position peaked at $519K in Q2 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • InceptionR reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • InceptionR sold 11,708 Viking Therapeutics shares in Q2 2026, an estimated $381K.
  • InceptionR first reported a position in Viking Therapeutics in Q2 2024 and held it in 3 quarters.
  • InceptionR's Viking Therapeutics position peaked at $519K in Q2 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on InceptionR's 13F filing for Q2 2026, filed 11 Aug 2026.